Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 3, Open-label, Single-dose, Multicenter Study Investigating Efficacy, Safety, and Tolerability of CSL222 (Etranacogene Dezaparvovec) Administered to Adolescent Male Subjects (≥ 12 to < 18 Years of Age) With Severe or Moderately Severe Hemophilia B

NCT07080905 is registered in ClinicalTrials.gov with CSL Behring as lead sponsor.

NCT NCT07080905
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07080905 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 3, Open-label, Single-dose, Multicenter Study Investigating Efficacy, Safety, and Tolerability of CSL222 (Etranacogene Dezaparvovec) Administered to Adolescent Male Subjects (≥ 12 to < 18 Years of Age) With Severe or Moderately Severe Hemophilia B
Lead sponsor
CSL Behring
Phase
Phase 3
Overall status
Recruiting
Start date
July 28, 2025
Completion date
October 24, 2033
Enrollment
20 (estimated)
Sites
16

Conditions

As the registry lists them; a condition with its own page is linked.

hemophilia b